Patients >80 years with atrial fibrillation were significantly less likely to receive warfarin than those <80 years (25.5% vs 61.5%, P<0.0001) and 5.46 times more likely to receive aspirin.
Observational (n=262)
No
Does advanced age (>80 years) influence the selection of antithrombotic therapy in elderly patients with non-valvular atrial fibrillation?
Advanced age (>80 years) is the largest contributing factor for withholding warfarin in preference to aspirin in elderly patients with atrial fibrillation, independent of recognized contraindications.
Odds Ratio: 5.46
Tasa de eventos absoluta: 25.5% vs 61.5%
valor p: p=<0.0001
Aim of study: To investigate the use of antithrombotic therapy in elderly patients with atrial fibrillation (AF). Methods: Data were collected retrospectively from the medical records of 262 AF patients >65 years, who were admitted to a Sydney teaching hospital over a 12‐month period. Results: Overall, 202 (79%) patients were discharged on some antithrombotic therapy. Patients 80 years were 5.46 times more likely to receive aspirin in preference to warfarin than their younger counterparts (P<0.0001). Conclusion: Warfarin is being withheld in AF patients ≥80 years for reasons other than recognised contraindications and is, therefore, potentially underutilised in the target elderly population. Further studies are necessary to determine whether this is appropriate.
Bajorek et al. (Fri,) conducted a observational in Atrial fibrillation (n=262). Age >80 years vs. Age <80 years was evaluated on Receipt of warfarin (OR 5.46, p=<0.0001). Patients >80 years with atrial fibrillation were significantly less likely to receive warfarin than those <80 years (25.5% vs 61.5%, P<0.0001) and 5.46 times more likely to receive aspirin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: